4 min read

ALCOA+ explained: why good documentation is a safety issue, not paperwork

In regulated healthcare and pharmaceutical work, there is a simple rule: if it was not documented, it did not happen. The ALCOA+ principles describe what good documentation looks like (Medicines and Healthcare products Regulatory Agency [MHRA], 2018), and they apply equally to a batch record, a labo
ALCOA+ explained why good documentation is a safety issue, not paperwork

In regulated healthcare and pharmaceutical work, there is a simple rule: if it was not documented, it did not happen. The ALCOA+ principles describe what good documentation looks like (Medicines and Healthcare products Regulatory Agency [MHRA], 2018), and they apply equally to a batch record, a laboratory notebook and a patient medication file.

I have kept regulated records throughout my career: in hospital pharmacy in Moldova and Romania, in Swiss community pharmacy, and in my research at the University of Basel. This article explains ALCOA+ and why it is fundamentally about safety.

What ALCOA+ stands for

The original five principles were later extended with four more, creating ALCOA+ (Pharmaceutical Inspection Co-operation Scheme [PIC/S], 2021).

PrincipleMeaningPharmacy exampleLaboratory or industry example
AttributableIt is clear who recorded it and whenEach dispensing entry is linked to the pharmacist's loginAnalyst initials and date on every entry
LegibleIt can be read and understood permanentlyClear, unambiguous notes in the patient fileNo unclear abbreviations in a batch record
ContemporaneousRecorded at the time of the activityAn ADR noted during the patient conversationWeighing recorded as it happens, not at the end of the day
OriginalThe first record, or a certified copyThe original prescription retainedRaw instrument data kept, not only the summary
AccurateCorrect, complete and truthfulCorrect dose and batch in the recordCalculations verified, errors corrected transparently
CompleteNothing missing, including repeatsAll medicines recorded, including self-medicationAll runs recorded, including failed ones
ConsistentChronological and in a standard formatDates and units used the same waySequence of events follows the procedure
EnduringLasts for the required retention periodRecords kept for the legally required timeData on validated, backed-up systems
AvailableCan be retrieved when neededMedication history accessible at every visitRecords retrievable for audits and inspections

Why documentation is a safety issue

It is tempting to see documentation as administration that takes time away from "real" work. In regulated environments, documentation is part of the real work.

Consider three situations:

  • A suspected adverse reaction. Without accurate dates, doses and concomitant medicines, a safety reviewer cannot assess causality, and a real signal may be missed.
  • A batch release. If records are incomplete, nobody can confirm that the product was made according to its authorisation, and a defective batch could reach patients.
  • A recall. Without traceable records of what was dispensed or distributed, the affected product cannot be found quickly.

In each case, poor documentation directly increases patient risk.

Common data integrity failures

Regulators, including the FDA, the UK MHRA and PIC/S, have published guidance on data integrity (MHRA, 2018; PIC/S, 2021; U.S. Food and Drug Administration [FDA], 2018) because the same failures appear repeatedly in inspections:

  • shared user accounts, which make records non-attributable;
  • data recorded on scraps of paper and transcribed later;
  • results repeated until they pass, with failed results not recorded;
  • changes made without an audit trail or a reason;
  • original electronic data deleted after printing (FDA, 2018).

Most of these failures do not start with bad intent. They start with time pressure and unclear habits, which is why culture and training matter as much as systems.

Correcting errors the right way

Mistakes happen. What matters is how they are corrected.

On paper, a correction is made with a single line through the original entry so it remains readable, with the new value, the date, the initials and, where relevant, a reason (European Commission, 2011b). In electronic systems, an audit trail captures the same information automatically (European Commission, 2011a).

The original must never disappear. Transparency about errors is a sign of a healthy quality culture.

Applying ALCOA+ in practice

In my pharmacy work, maintaining accurate patient medication records and documenting suspected adverse reactions at the time of the conversation are everyday applications of ALCOA+. In hospital practice, rigorous up-to-date patient and prescription records were essential for safe peri-operative care.

In my thesis research, I produced structured documentation and data analysis outputs consistent with regulatory research standards. That included linking every result back to raw data and documenting each analysis step.

My GCP training in 2024 reinforced the same principles for clinical research, where source data must support everything reported about trial participants (International Council for Harmonisation [ICH], 2025).

Why this matters to employers

Data integrity findings are among the most common observations in GMP, GCP and pharmacovigilance inspections (FDA, 2018; MHRA, 2018). Companies need people for whom ALCOA+ is a habit, not a training slide.

My experience across pharmacy, hospital and laboratory environments has given me exactly that habit: documenting contemporaneously, completely and transparently.

Key takeaways

  • ALCOA+ defines trustworthy records: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available.
  • Poor documentation directly increases risk to patients.
  • Data integrity depends on culture and habits as much as on systems.

References

European Commission. (2011a). EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use – Annex 11: Computerised systems. https://health.ec.europa.eu

European Commission. (2011b). EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use – Chapter 4: Documentation. https://health.ec.europa.eu

International Council for Harmonisation. (2025). Guideline for good clinical practice E6(R3). https://www.ich.org

Medicines and Healthcare products Regulatory Agency. (2018). 'GXP' data integrity guidance and definitions (Rev. 1). https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

Pharmaceutical Inspection Co-operation Scheme. (2021). Good practices for data management and integrity in regulated GMP/GDP environments (PI 041-1). https://picscheme.org

U.S. Food and Drug Administration. (2018). Data integrity and compliance with drug CGMP: Questions and answers. Guidance for industry. https://www.fda.gov